Navinci will attend SITC on November 8th – 12th in Boston, US. We will show our new product line with target-specific protein–protein interactions for functional studies of PD1 signaling in situ, based on our proprietary NaveniTM Technology. Meet us at booth 723!
The importance of studying PD1/PD-L1 interaction and phosphorylated PD1 in situ
- T cells can kill cancer cells, but they are inhibited by the interaction of their surface protein PD-1 with the PD-L1 protein on the cancer cells.
- Antibodies directed against PD-1 can block this inhibition allowing T cells to kill the cancer cells.
- This is the basis for modern immunotherapy in cancer – but to know if the immunotherapy can be effective, it is of interest to measure the levels of PD-1 and PD-L1 proteins and their activity states in cancer tissue. This cannot be measured in blood.
- T cells can kill cancer cells, but they are inhibited by the interaction of their surface protein PD-1 with the PD-L1 protein on the cancer cells.
- Antibodies directed against PD-1 can block this inhibition allowing T cells to kill the cancer cells.
- This is the basis for modern immunotherapy in cancer – but to know if the immunotherapy can be effective, it is of interest to measure the levels of PD-1 and PD-L1 proteins and their activity states in cancer tissue. This cannot be measured in blood.
NaveniTM technology offers deep understanding of biological functions
Navinci now provides a comprehensive package of products to deepen the understanding of PD1 signaling and functions. Naveni PD1/PD-L1 is a tool for direct visualization of the interaction between PD-1 and PD-L1. To complement the Naveni PD1/PD-L1 kit, Naveni pY PD1 and Naveni PD1/SHP-2 (coming soon) sensitively detect different steps in the PD-1/PD-L1 inhibitory pathway activation.
The NaveniTM PD1/PD-L1 was validated using human FFPE tissue. The PD1/PD-L1 interaction was verified in: Hodgkin’s lymphoma, Tonsil, Acinar Adenocarcinoma lung, Squamous cell lung carcinoma, Malignant Melanoma, Colon adenocarcinoma, and Pancreatic ductal adenocarcinoma. Go to product
The NaveniTM pY PD1 was validated in human FFPE, Tonsil tissue, and compared with IHC. NaveniTM pY PD1 specifically detects phosphorylated PD1. IHC staining of phosphorylated PD1 gave unspecific staining. Go to product
Navinci Technology
Learn how to maximize information from every analysis by localizing and quantifying proteins, their interactions, and modifications in situ at a molecular level. In situ methods are commonly used in the cancer research field, and studies of protein-protein interactions (PPI) and protein translational modifications (PTM) are essential for:
- Deep biological knowledge
- Biomarker discovery
- Patient stratification
- Drug testing
- Treatment validation
All our products are based on our proprietary Naveni Proximity Ligation technology with dual antibody recognition giving you more specific and sensitive detection of your target of interest. Click here to read about the technology.
To our flexible products – to use with your primary antibodies
To our specific products – for the precise detection of phosphorylated Met, VEGFR2, EGFR, HER2, and PDGFR-beta.
Navinci team at SITC
Agata Wicher (CSO), Ida Hansson (sales specialist), Inge Cyrén (sales specialist), Lena Beckman (Marketing and Product Manager), and Robert Gunnarsson (CEO)
We would love to meet you; please book a meeting with us here